Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994757 | 0.91 | CYP11B2 (0.46) | GPR119USP2SMN1; SMN2EPHX2 | |
| SCHEMBL18263252 | 0.89 | GPR119 (0.47) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL16054753 | 0.86 | GPR119 (0.49) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL1474868 | 0.85 | USP2 (0.49) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL22305158 | 0.85 | USP2 (0.49) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL3245456 | 0.84 | GPR119 (0.46) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL29024806 | 0.84 | USP2 (0.47) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL29326315 | 0.84 | USP2 (0.47) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL16969327 | 0.84 | USP2 (0.47) | GPR119USP2SMN1; SMN2EPHX2HPGD | |
| SCHEMBL2343400 | 0.84 | GPR119 (0.50) | GPR119USP2SMN1; SMN2EPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539295-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4680343-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250222116-A1 | PARP-1 DEGRADATION AGENT AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025136944-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2519526-B1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2519526-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-07 | — | — | EP | disclosed |
| WO-2012098387-A1 | 6, 7-RING-FUSED TRIAZOLO [4, 3 - B] PYRIDAZINE DERIVATIVES AS PIM INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012020217-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | US | disclosed |
| WO-2011080510-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | GPR119 1443/4885USP2 740/4885SMN1; SMN2 1781/4885 |
| US-20250222116-A1 | PARP-1 DEGRADATION AGENT AND USE THEREOF | PARP1, PARP11, PARP2 | GPR119 3709/4885USP2 2937/4885SMN1; SMN2 1663/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | GPR119 4442/4885USP2 673/4885SMN1; SMN2 1183/4885 |
| US-12539295-B2 | IRAK degraders and uses thereof | IRAK2, IRAK4, IRAK3 | GPR119 812/4885USP2 551/4885SMN1; SMN2 191/4885 |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | PIM1, PIM2, PIM3 | GPR119 1305/4885USP2 3646/4885SMN1; SMN2 4219/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | GPR119 932/4885USP2 684/4885SMN1; SMN2 960/4885 |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, IDH3B, DHFR | GPR119 1390/4885USP2 4754/4885SMN1; SMN2 1688/4885 |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | GPR119 616/4885USP2 2488/4885SMN1; SMN2 2162/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | GPR119 4469/4885USP2 1088/4885SMN1; SMN2 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.